News | October 21, 2022
Aarti Drugs Q2 FY23 revenue up 19%; Profit down 5.6%
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Aarti Drugs Limited has reported total income of Rs. 622.22 crores during the quarter ended June 30, 2022.
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The company posted net profit f Rs.85.45 crores for the period ended June 30, 2020.
Aarti Drugs has reported total income of Rs.2159.30 crores during the 12 months period ended March 31, 2021
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Subscribe To Our Newsletter & Stay Updated
